Medicines

Find Medicines

Search 21,000+ medicines by brand, generic, indication, or drug class

Medicine Indications Drug Classes
    Showing all medicines (21591 total)

    Relikof Kidz

    Citric Acid Monohydrate
    Syrup 31.25 mg/5 ml Allopathic Cough suppressant

    Indications

    Dry cough

    Indication detailsView
    Citric Acid Monohydrate is indicated for the management of dry cough.
    Therapeutic classView
    Cough suppressant
    PharmacologyView
    Citric Acid Monohydrate helps to reduce the dry cough and soothes the throat from any related discomfort and pain. Citric Acid is a demulcent which relieves irritation of the mucous membrane in the throat by forming a protective film. Citric Acid is absorbed after oral administration. It is found naturally in the body and is widely distributed.
    DosageView
    1-5 years: 5 ml upto 4 times daily
    6-12 years: 10 ml upto 4 times daily
    >12 years & Adults: 20 ml upto 3-4 times daily
    Side effectsView
    There are no known side effects from using this medicine when used as directed. If taken excessively above the stated dose, glycerol present in the medicine may cause headache, stomach upset and diarrhea.
    ContraindicationsView
    It is contraindicated for the hypersensitivity to any of the ingredients of this medicine.
    PrecautionsView
    Patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase insufficiency should not take this medicine.
    InteractionsView
    No drug-drug interaction has been found.
    Pregnancy & lactationView
    There are no or limited amount of data from the use of Citric Acid Monohydrate in pregnant women. There is insufficient information on the excretion of Citric Acid Monohydrate & its metabolites in human milk.
    StorageView
    Keep in a cool and dry place, away from light. Keep out of the reach of children.

    Relise

    Aceclofenac
    Tablet 100 mg Allopathic Drugs for Osteoarthritis

    Indications

    Spondylitis

    Indication detailsView
    Aceclofenac is indicated for the relief of pain and inflammation in osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, toothache, trauma and lumbago.
    Therapeutic classView
    Drugs for Osteoarthritis, Drugs used for Rheumatoid Arthritis, Non-steroidal Anti-inflammatory Drugs (NSAIDs)
    PharmacologyView

    Aceclofenac is a non-steroidal drug with anti-inflammatory and analgesic properties. It is a potent inhibitor of the enzyme cyclooxygenase, which is involved in the production of prostaglandin. After oral administration, it is rapidly and completely absorbed an unchanged drug.

    DosageView

    Extended release tablet: The recommended dose in adults is one 200 mg Aceclofenac tablet daily or as prescribed by the physician.
    Film coated tablet: The recommended dose in adults is 100 mg, twice daily.

    Side effectsView

    Aceclofenac is a non-steroidal drug with anti-inflammatory and analgesic properties. It is a potent inhibitor of the enzyme cyclooxygenase, which is involved in the production of prostaglandin. After oral administration, it is rapidly and completely absorbed an unchanged drug.

    ContraindicationsView

    Aceclofenac is contraindicated in patients with known hypersensitivity to it or in whom aspirin or NSAIDs precipitate attacks of asthma.

    PrecautionsView

    Caution should be exercised to patients with active or suspected peptic ulcer or gastro-intestinal bleeding moderate to severe hepatic impairment and cardiac or renal impairment. Caution should also be exercised in patients suffering from dizziness or urticaria.

    InteractionsView
    No significant drug interactions has not been observed but close monitoring of patients is required when it is used with:
    • Lithium and Digoxin: may increase plasma concentration of lithium and digoxin.
    • Diuretics: may interact the activity of diuretics.
    • Anticoagulants: may enhance the activity of anticoagulant.
    • Methotrexate: may increase the plasma level of methotrexate.
    Pregnancy & lactationView

    The use of Aceclofenac should be avoided in pregnancy and lactation unless the potential benefits to the other outweigh the possible risks to the fetus.

    Pediatric usageView
    There are no clinical data on the use of Aceclofenac in children.
    StorageView

    keep in a dry place away from light and heat. Keep out of the reach of children.

    Relitch

    Betamethasone + Phenylephrine + Lignocaine
    Rectal Ointment 0.05%+0.1%+2.5% Allopathic Phlebotonic & Vascular protecting preparation

    Indications

    Piles

    Indication detailsView
    Local anorectal conditions like haemorrhoids and fissures where, there is inflammation & pain.
    Therapeutic classView
    4-Quinolone preparations, Phlebotonic & Vascular protecting preparation
    PharmacologyView
    Betamethasone is a corticosteroid with mainly glucocorticoid activity. It induces phospholipase A2 inhibitory lipase (lipocortins) and sequentially inhibits the release of arachidonic acid, thereby depressing the formation, release, and activity of prostaglandins, leukotrienes, and other inflammatory mediators.

    Phenylephrine is a sympathomimetic with mainly direct effects on alpha-adrenergic receptors and weak beta-adrenergic activity. It causes vasoconstriction of the arterioles of the nasal mucosa and conjunctiva; activates the dilator muscle of the pupil to cause contraction; produces vasoconstriction of arterioles in the body and produces systemic arterial vasoconstriction.

    Lidocaine alters signal conduction in neurons by blocking the fast voltage-gated Na+ channels in the neuronal cell membrane responsible for signal propagation. With sufficient blockage, the membrane of the postsynaptic neuron will not depolarize and will thus fail to transmit an action potential.
    DosageView
    Apply locally 2 or 3 times daily initially, using the applicator if internal administration is required, When inflammation is subsiding once-daily application is sufficient in most cases,
    Side effectsView
    As with all topical corticosteroids, its use for prolonged periods, may cause systemic absorption, specially in children. Prolonged and intensive treatment with active corticosteroid preparations may also cause local atrophic changes in the skin. There are reports of pigmentation changes and hypertrichosis with topical steroids, and in this situation it should be discontinued. Some patients may experience burning upon application, specially if the mucous membrane is not intact.
    ContraindicationsView
    Topical corticosteroids are contraindicated in: Primarily infected skin lesions caused by viral infections e.g herpes simplex, vaccinia or varicella (chicken pox), by bacteria e.g impetigo, by fungal infections e.g candidiasis, tineasis or by tuberculous infection of the anal region; Sensitivity to any of the components of the product; Dermatoses in children under 1 year of age.
    PrecautionsView
    Long-term continuous treatment should be avoided. Discontinue if sensitization occurs.
    InteractionsView
    Not known
    Pregnancy & lactationView
    The safe use of topical corticosteroids in human pregnancy has not been fully established. Topical administration of corticosteroids to pregnant animals can cause abnormalities of fetal development including cleft palate and intrauterine growth retardation.

    Therefore, there may be a very small risk of such effects in the human fetus. So, it should not be used unnecessarily in large amounts or for prolonged period.

    Reliv

    Paracetamol
    Oral Suspension 120 mg/5 ml Allopathic Non opioid analgesics

    Indications

    Toothache

    Indication detailsView
    Paracetamol is indicated for fever, common cold and influenza, headache, toothache, earache, bodyache, myalgia, neuralgia, dysmenorrhoea, sprains, colic pain, back pain, post-operative pain, postpartum pain, inflammatory pain and post vaccination pain in children. It is also indicated for rheumatic & osteoarthritic pain and stiffness of joints.
    Therapeutic classView
    Non opioid analgesics
    PharmacologyView
    Paracetamol has analgesic and antipyretic properties with weak anti-inflammatory activity. Paracetamol (Acetaminophen) is thought to act primarily in the CNS, increasing the pain threshold by inhibiting both isoforms of cyclooxygenase, COX-1, COX-2, and COX-3 enzymes involved in prostaglandin (PG) synthesis. Paracetamol is a para aminophenol derivative, has analgesic and antipyretic properties with weak anti-inflammatory activity. Paracetamol is one of the most widely used, safest and fast acting analgesic. It is well tolerated and free from various side effects of aspirin.
    DosageView
    Tablet:
    • Adult: 1-2 tablets every 4 to 6 hours up to a maximum of 4 gm (8 tablets) daily.
    • Children (6-12 years): ½ to 1 tablet 3 to 4 times daily. For long term treatment it is wise not to exceed the dose beyond 2.6 gm/day.
    Extended Release Tablet:
    • Adults & Children over 12 years: Two tablets, swallowed whole, every 6 to 8 hours (maximum of 6 tablets in any 24 hours).The tablet must not be crushed.
    Syrup/Suspension:
    • Children under 3 months: 10 mg/kg body weight (reduce to 5 mg/kg if jaundiced) 3 to 4 times daily.
    • 3 months to below 1 year: ½ to 1 teaspoonful 3 to 4 times daily.
    • 1-5 years: 1 -2 teaspoonful 3 to 4 times daily.
    • 6-12 years: 2-A teaspoonful 3 to 4 times daily.
    • Adults: 4-8 teaspoonful 3 to 4 times daily.
    Suppository:
    • Children 3-12 months: 60-120 mg,4 times daily.
    • Children 1-5 years: 125-250 mg 4 times daily.
    • Children 6-12 years: 250-500 mg 4 times daily.
    • Adults & children over 12 years: 0.5-1 gm 4 times daily.
    Paediatric Drop:
    • Children Upto 3 months: 0.5 ml (40 mg)
    • 4 to 11 months: 1.0 ml (80 mg)
    • 7 to 2 years: 1.5 ml (120 mg). Do not exceed more than 5 dose daily for a maximum of 5 days.
    Paracetamol tablet with actizorb technology: It dissolves up to five times faster than standard Paracetamol tablets. It is a fast acting and safe analgesic with marked antipyretic property. It is specially suitable for patients who, for any reason, can not tolerate aspirin or other analgesics.
    • Adults and children (aged 12 years and over): Take 1 to 2 Tablets every four to six hours as needed. Do not take more than 8 caplets in 24 hours.
    • Children (7 to 11 years): Take ½-1 Tablet every four to six hours as needed. Do not take more than 4 caplets in 24 hours. Not recommended in children under 7 years.
    Side effectsView
    Side effects of paracetamol are usually mild, though haematological reactions including thrombocytopenia, leucopenia, pancytopenia, neutropenia, and agranulocytosis have been reported. Pancreatitis, skin rashes, and other allergic reactions occur occasionally.
    ContraindicationsView
    It is contraindicated in known hypersensitivity to Paracetamol.
    PrecautionsView
    Paracetamol should be given with caution to patients with impaired kidney or liver function. Paracetamol should be given with care to patients taking other drugs that affect the liver.
    InteractionsView
    Patients who have taken barbiturates, tricyclic antidepressants and alcohol may show diminished ability to metabolise large doses of Paracetamol. Alcohol can increase the hepatotoxicity of Paracetamol overdosage. Chronic ingestion of anticonvulsants or oral steroid contraceptives induce liver enzymes and may prevent attainment of therapeutic Paracetamol levels by increasing first-pass metabolism or clearance.
    Pregnancy & lactationView
    Pregnancy category B according to USFDA. This drug should be used during pregnancy only if clearly needed
    Overdose effectsView
    Symptoms of Paracetamol overdose in the first 24 hours are pallor, nausea, vomiting, anorexia and abdominal pain. Liver damage may become apparent 12-48 hours after ingestion. Abnormalities of glucose metabolism and metabolic acidosis may occur.
    StorageView
    Keep in a dry place away from light and heat. Keep out of the reach of children.

    Reliv

    Paracetamol
    Tablet 500 mg Allopathic Non opioid analgesics

    Indications

    Toothache

    Indication detailsView
    Paracetamol is indicated for fever, common cold and influenza, headache, toothache, earache, bodyache, myalgia, neuralgia, dysmenorrhoea, sprains, colic pain, back pain, post-operative pain, postpartum pain, inflammatory pain and post vaccination pain in children. It is also indicated for rheumatic & osteoarthritic pain and stiffness of joints.
    Therapeutic classView
    Non opioid analgesics
    PharmacologyView
    Paracetamol has analgesic and antipyretic properties with weak anti-inflammatory activity. Paracetamol (Acetaminophen) is thought to act primarily in the CNS, increasing the pain threshold by inhibiting both isoforms of cyclooxygenase, COX-1, COX-2, and COX-3 enzymes involved in prostaglandin (PG) synthesis. Paracetamol is a para aminophenol derivative, has analgesic and antipyretic properties with weak anti-inflammatory activity. Paracetamol is one of the most widely used, safest and fast acting analgesic. It is well tolerated and free from various side effects of aspirin.
    DosageView
    Tablet:
    • Adult: 1-2 tablets every 4 to 6 hours up to a maximum of 4 gm (8 tablets) daily.
    • Children (6-12 years): ½ to 1 tablet 3 to 4 times daily. For long term treatment it is wise not to exceed the dose beyond 2.6 gm/day.
    Extended Release Tablet:
    • Adults & Children over 12 years: Two tablets, swallowed whole, every 6 to 8 hours (maximum of 6 tablets in any 24 hours).The tablet must not be crushed.
    Syrup/Suspension:
    • Children under 3 months: 10 mg/kg body weight (reduce to 5 mg/kg if jaundiced) 3 to 4 times daily.
    • 3 months to below 1 year: ½ to 1 teaspoonful 3 to 4 times daily.
    • 1-5 years: 1 -2 teaspoonful 3 to 4 times daily.
    • 6-12 years: 2-A teaspoonful 3 to 4 times daily.
    • Adults: 4-8 teaspoonful 3 to 4 times daily.
    Suppository:
    • Children 3-12 months: 60-120 mg,4 times daily.
    • Children 1-5 years: 125-250 mg 4 times daily.
    • Children 6-12 years: 250-500 mg 4 times daily.
    • Adults & children over 12 years: 0.5-1 gm 4 times daily.
    Paediatric Drop:
    • Children Upto 3 months: 0.5 ml (40 mg)
    • 4 to 11 months: 1.0 ml (80 mg)
    • 7 to 2 years: 1.5 ml (120 mg). Do not exceed more than 5 dose daily for a maximum of 5 days.
    Paracetamol tablet with actizorb technology: It dissolves up to five times faster than standard Paracetamol tablets. It is a fast acting and safe analgesic with marked antipyretic property. It is specially suitable for patients who, for any reason, can not tolerate aspirin or other analgesics.
    • Adults and children (aged 12 years and over): Take 1 to 2 Tablets every four to six hours as needed. Do not take more than 8 caplets in 24 hours.
    • Children (7 to 11 years): Take ½-1 Tablet every four to six hours as needed. Do not take more than 4 caplets in 24 hours. Not recommended in children under 7 years.
    Side effectsView
    Side effects of paracetamol are usually mild, though haematological reactions including thrombocytopenia, leucopenia, pancytopenia, neutropenia, and agranulocytosis have been reported. Pancreatitis, skin rashes, and other allergic reactions occur occasionally.
    ContraindicationsView
    It is contraindicated in known hypersensitivity to Paracetamol.
    PrecautionsView
    Paracetamol should be given with caution to patients with impaired kidney or liver function. Paracetamol should be given with care to patients taking other drugs that affect the liver.
    InteractionsView
    Patients who have taken barbiturates, tricyclic antidepressants and alcohol may show diminished ability to metabolise large doses of Paracetamol. Alcohol can increase the hepatotoxicity of Paracetamol overdosage. Chronic ingestion of anticonvulsants or oral steroid contraceptives induce liver enzymes and may prevent attainment of therapeutic Paracetamol levels by increasing first-pass metabolism or clearance.
    Pregnancy & lactationView
    Pregnancy category B according to USFDA. This drug should be used during pregnancy only if clearly needed
    Overdose effectsView
    Symptoms of Paracetamol overdose in the first 24 hours are pallor, nausea, vomiting, anorexia and abdominal pain. Liver damage may become apparent 12-48 hours after ingestion. Abnormalities of glucose metabolism and metabolic acidosis may occur.
    StorageView
    Keep in a dry place away from light and heat. Keep out of the reach of children.

    Reliv Plus

    Paracetamol + Caffeine
    Tablet 500 mg+65 mg Allopathic Non opioid analgesics

    Indications

    Toothache

    Indication detailsView
    The is indicated in the following condition-
    • Headache
    • Migraine
    • Toothache
    • Neuralgia
    • Feverishness
    • Period pain
    • Sore throat
    • Backache
    • Help to reduce the temperature
    • Aches and pain of colds and flu
    Therapeutic classView
    Non opioid analgesics
    PharmacologyView
    This is a combination of Paracetamol and Caffeine. Paracetamol has analgesic and antipyretic properties with weak anti-inflammatory activity. Caffeine is an alkaloid which is a theophylline-like xanthine derivative. By intermolecular association with Paracetamol, Caffeine increases the solubility and transmembrane permeation of Paracetamol. In addition, Caffeine increases the pain threshold and tolerance of pain. Caffeine has also an intrinsic power to raise vessel tone in the brain, which provides another benefit to treat migraine and headache.
    DosageView
    Adult dose: 1-2 tablets every 4-6 hours. Maximum dose: 8 tablets daily.
    Child dose: Not recommended for children below 12 years.
    Side effectsView
    Side effects of paracetamol are usually mild, though haematological reactions including thrombocytopenia, leukopenia, pancytopenia, neutropenia, and agranulocytosis have been reported. Pancreatitis, skin rashes, and other allergic reactions occur occasionally.
    ContraindicationsView
    Paracetamol is contraindicated in patients with severe renal function impairment and hepatic disease (Viral Hepatitis). Known hypersensitivity to paracetamol or caffeine.
    PrecautionsView
    Paracetamol & Caffeine should be given cautiously in the following cases: In patients with hepatic or renal failure, in patients taking other hepatotoxic medication. Prolonged use of the drug without consulting a physician should be avoided.
    InteractionsView
    May reduce serum levels with anticonvulsants (e.g. phenytoin, barbiturates, carbamazepine). May enhance the anticoagulant effect of warfarin and other coumarins with prolonged use. Accelerated absorption with metoclopramide and domperidone. May increase serum levels with probenecid. May increase serum levels of chloramphenicol. May reduce absorption with colestyramine within 1 hr of admin. May cause severe hypothermia with phenothiazine.
    Pregnancy & lactationView
    Pregnant mothers should consult with doctors before taking Paracetamol & Caffeine. Paracetamol & Caffeine can be taken whilst breast feeding.
    Overdose effectsView
    Symptoms of Paracetamol overdose in the first 24 hours are pallor, nausea, vomiting, anorexia and abdominal pain. Liver damage may become apparent 12 to 40 hours after ingestion. Abnormalities of glucose metabolism and metabolic acidosis may occur.
    StorageView
    Store in a cool and dry place, protect from light and moisture.Keep all medicines out of the reach of the children.

    Relivix

    Citric Acid Monohydrate
    Syrup 125 mg/5 ml Allopathic Cough suppressant

    Indications

    Dry cough

    Indication detailsView
    Citric Acid Monohydrate is indicated for the management of dry cough.
    Therapeutic classView
    Cough suppressant
    PharmacologyView
    Citric Acid Monohydrate helps to reduce the dry cough and soothes the throat from any related discomfort and pain. Citric Acid is a demulcent which relieves irritation of the mucous membrane in the throat by forming a protective film. Citric Acid is absorbed after oral administration. It is found naturally in the body and is widely distributed.
    DosageView
    1-5 years: 5 ml upto 4 times daily
    6-12 years: 10 ml upto 4 times daily
    >12 years & Adults: 20 ml upto 3-4 times daily
    Side effectsView
    There are no known side effects from using this medicine when used as directed. If taken excessively above the stated dose, glycerol present in the medicine may cause headache, stomach upset and diarrhea.
    ContraindicationsView
    It is contraindicated for the hypersensitivity to any of the ingredients of this medicine.
    PrecautionsView
    Patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase insufficiency should not take this medicine.
    InteractionsView
    No drug-drug interaction has been found.
    Pregnancy & lactationView
    There are no or limited amount of data from the use of Citric Acid Monohydrate in pregnant women. There is insufficient information on the excretion of Citric Acid Monohydrate & its metabolites in human milk.
    StorageView
    Keep in a cool and dry place, away from light. Keep out of the reach of children.

    Relivix Kids

    Citric Acid Monohydrate
    Syrup 31.25 mg/5 ml Allopathic Cough suppressant

    Indications

    Dry cough

    Indication detailsView
    Citric Acid Monohydrate is indicated for the management of dry cough.
    Therapeutic classView
    Cough suppressant
    PharmacologyView
    Citric Acid Monohydrate helps to reduce the dry cough and soothes the throat from any related discomfort and pain. Citric Acid is a demulcent which relieves irritation of the mucous membrane in the throat by forming a protective film. Citric Acid is absorbed after oral administration. It is found naturally in the body and is widely distributed.
    DosageView
    1-5 years: 5 ml upto 4 times daily
    6-12 years: 10 ml upto 4 times daily
    >12 years & Adults: 20 ml upto 3-4 times daily
    Side effectsView
    There are no known side effects from using this medicine when used as directed. If taken excessively above the stated dose, glycerol present in the medicine may cause headache, stomach upset and diarrhea.
    ContraindicationsView
    It is contraindicated for the hypersensitivity to any of the ingredients of this medicine.
    PrecautionsView
    Patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase insufficiency should not take this medicine.
    InteractionsView
    No drug-drug interaction has been found.
    Pregnancy & lactationView
    There are no or limited amount of data from the use of Citric Acid Monohydrate in pregnant women. There is insufficient information on the excretion of Citric Acid Monohydrate & its metabolites in human milk.
    StorageView
    Keep in a cool and dry place, away from light. Keep out of the reach of children.

    Relmas

    Baclofen
    Tablet 10 mg Allopathic Centrally acting Skeletal Muscle Relaxants

    Indications

    Trigeminal neuralgia

    Indication detailsView
    Baclofen is indicated in-
    • spasticity resulting from multiple sclerosis
    • flexor spasms and concomitant pain, clonus and muscular rigidity
    • skeletal muscle spasm resulting from rheumatic disorders
    • spinal cord injuries and other spinal cord diseases
    • cerebrovascular accidents or neoplastic or degenerative brain disease
    Therapeutic classView
    Centrally acting Skeletal Muscle Relaxants
    PharmacologyView
    Baclofen inhibits both monosynaptic and polysynaptic reflexes at the spinal level by stimulating the GABAB receptors, which inhibits the release of glutamate and aspartate. It may also act at intraspinal sites producing CNS depression. Baclofen also exerts an antinociceptive effect.
    DosageView
    Adult & children over 10 years: 5 mg 3 times daily, preferably with or after food, gradually increased; max. 100 mg daily.

    Children <10 years    : Treatment is usually started with 2.5 mg (2.5 ml) given 4 times daily then raised according to requirement. Daily maintenance dose-
    • 12 month-2 years: 10-20 mg (10-20 ml)
    • 2 years-6 years: 20-30 mg (20-30 ml)
    • 6 years-10 years: 30-60 mg (30-60 ml)
    Side effectsView
    The most common adverse reactions associated with Baclofen are transient drowsiness, daytime sedation, dizziness, weakness and fatigue.
    • Central Nervous System: Headache (<10%), insomnia (<10%), and rarely, euphoria, excitement, depression, confusion, hallucinations, paraesthesia, nightmares, muscle pain, tinnitus, slurred speech, co-ordination disorder, tremor, rigidity, dystonia, ataxia, blurred vision, nystagmus, strabismus, miosis, mydriasis, diplopia, dysarthria, epileptic seizures, respiratory depression.
    • Cardiovascular: Hypotension (<10%), rare instances of dyspnoea, palpitation, chest pain, syncope.
    • Gastrointestinal: Nausea (approximately 10%), constipation (<10%) and rarely, dry mouth, anorexia, taste disorder, abdominal pain, vomiting, diarrhoea and positive test for occult blood in stool.
    • Genitourinary: Urinary frequency (<10%) and rarely, enuresis, urinary retention, dysuria, impotence, inability to ejaculate, nocturia, haematuria.
    • Other: Instances of rash, pruritus, ankle oedema, excessive perspiration, weight gain, nasal congestion, visual disturbances, hepatic function disorders and paradoxical increase in spasticity. Muscular hypotonia of a degree sufficient to make walking or movement difficult may occur but is usually relieved by readjusting the dosage. For this purpose, the daytime dosage may be reduced and the evening dosage increased.
    ContraindicationsView
    Baclofen is contraindicated in patients with hypersensitivity to any component of this product.
    PrecautionsView
    • Lower doses (approximately 5 mg per day) should be used for patients with impaired renal function or those undergoing chronic haemodialysis.
    • Patients suffering not only from spasticity but also from psychotic disorders, schizophrenia, depressive or manic disorders or confusional states should be treated cautiously and closely monitored as exacerbations of these disorders may occur.
    • In patients with epilepsy and muscle spasticity, Baclofen may be used under appropriate supervision and provided that adequate anticonvulsive therapy is continued. Lowering of the convulsion threshold may occur and seizures have been reported after the cessation of Baclofen therapy or with overdose.
    • Baclofen should be used with caution in patients with or with a history of peptic ulcers, cerebrovascular diseases, or hepatic, renal or respiratory failure.
    • Careful monitoring of respiratory and cardiovascular function is essential especially in patients with cardiopulmonary disease and respiratory muscle weakness.
    • During treatment with Baclofen, neurogenic disturbances affecting emptying of the bladder may improve. However in patients with preexisting sphincter hypertonia, acute retention of urine may occur. Baclofen should be used with caution in these circumstances.
    • Baclofen has not significantly benefited patients with stroke. These patients have also shown poor tolerance to the medicine.
    • Appropriate laboratory tests should be performed periodically in patients with hepatic diseases or diabetes mellitus to ensure that no medicine induced changes in these underlying diseases have occurred.
    InteractionsView
    • Increased sedation may occur if Baclofen is taken with agents acting on the central nervous system, alcohol or synthetic opiates. The risk of respiratory depression is also increased.
    • Combined treatment with Baclofen and antihypertensives is likely to increase the fall in blood pressure; therefore the dosage of antihypertensive medication should be adjusted accordingly.
    • The concomitant administration of Baclofen and tricyclic antidepressants may potentiate the pharmacological effects of Baclofen resulting in pronounced muscular hypotonia.
    • In patients with Parkinsons disease receiving treatment with Baclofen and levodopa and carbidopa, there have been several reports of mental confusion, hallucinations, headaches, nausea and agitation.
    • The concurrent use of MAO inhibitors and Baclofen may result in increased CNS depressant effects. Caution is advised and the dosage of one or both agents should be adjusted accordingly.
    • Caution should be exercised when administering Baclofen and magnesium sulphate or other neuromuscular blocking agents since a synergistic effect may theoretically occur.
    Pregnancy & lactationView
    Pregnancy category B3. Safe use of Baclofen during pregnancy has not been established. Baclofen crosses the placental barrier. Baclofen should only be administered to pregnant women when in the judgement of the physician concludes that the potential benefits outweigh the possible hazards. Baclofen is excreted in breast milk however evidence to date suggests that the quantities are so small that no undesirable effects on the infant would be expected.
    Overdose effectsView
    Gastric lavage is important in case of severe overdose.
    StorageView
    Keep below 30°C temperature, away from light & moisture. Keep out of the reach of children.

    Relofen

    Baclofen
    Tablet 10 mg Allopathic Centrally acting Skeletal Muscle Relaxants

    Indications

    Trigeminal neuralgia

    Indication detailsView
    Baclofen is indicated in-
    • spasticity resulting from multiple sclerosis
    • flexor spasms and concomitant pain, clonus and muscular rigidity
    • skeletal muscle spasm resulting from rheumatic disorders
    • spinal cord injuries and other spinal cord diseases
    • cerebrovascular accidents or neoplastic or degenerative brain disease
    Therapeutic classView
    Centrally acting Skeletal Muscle Relaxants
    PharmacologyView
    Baclofen inhibits both monosynaptic and polysynaptic reflexes at the spinal level by stimulating the GABAB receptors, which inhibits the release of glutamate and aspartate. It may also act at intraspinal sites producing CNS depression. Baclofen also exerts an antinociceptive effect.
    DosageView
    Adult & children over 10 years: 5 mg 3 times daily, preferably with or after food, gradually increased; max. 100 mg daily.

    Children <10 years    : Treatment is usually started with 2.5 mg (2.5 ml) given 4 times daily then raised according to requirement. Daily maintenance dose-
    • 12 month-2 years: 10-20 mg (10-20 ml)
    • 2 years-6 years: 20-30 mg (20-30 ml)
    • 6 years-10 years: 30-60 mg (30-60 ml)
    Side effectsView
    The most common adverse reactions associated with Baclofen are transient drowsiness, daytime sedation, dizziness, weakness and fatigue.
    • Central Nervous System: Headache (<10%), insomnia (<10%), and rarely, euphoria, excitement, depression, confusion, hallucinations, paraesthesia, nightmares, muscle pain, tinnitus, slurred speech, co-ordination disorder, tremor, rigidity, dystonia, ataxia, blurred vision, nystagmus, strabismus, miosis, mydriasis, diplopia, dysarthria, epileptic seizures, respiratory depression.
    • Cardiovascular: Hypotension (<10%), rare instances of dyspnoea, palpitation, chest pain, syncope.
    • Gastrointestinal: Nausea (approximately 10%), constipation (<10%) and rarely, dry mouth, anorexia, taste disorder, abdominal pain, vomiting, diarrhoea and positive test for occult blood in stool.
    • Genitourinary: Urinary frequency (<10%) and rarely, enuresis, urinary retention, dysuria, impotence, inability to ejaculate, nocturia, haematuria.
    • Other: Instances of rash, pruritus, ankle oedema, excessive perspiration, weight gain, nasal congestion, visual disturbances, hepatic function disorders and paradoxical increase in spasticity. Muscular hypotonia of a degree sufficient to make walking or movement difficult may occur but is usually relieved by readjusting the dosage. For this purpose, the daytime dosage may be reduced and the evening dosage increased.
    ContraindicationsView
    Baclofen is contraindicated in patients with hypersensitivity to any component of this product.
    PrecautionsView
    • Lower doses (approximately 5 mg per day) should be used for patients with impaired renal function or those undergoing chronic haemodialysis.
    • Patients suffering not only from spasticity but also from psychotic disorders, schizophrenia, depressive or manic disorders or confusional states should be treated cautiously and closely monitored as exacerbations of these disorders may occur.
    • In patients with epilepsy and muscle spasticity, Baclofen may be used under appropriate supervision and provided that adequate anticonvulsive therapy is continued. Lowering of the convulsion threshold may occur and seizures have been reported after the cessation of Baclofen therapy or with overdose.
    • Baclofen should be used with caution in patients with or with a history of peptic ulcers, cerebrovascular diseases, or hepatic, renal or respiratory failure.
    • Careful monitoring of respiratory and cardiovascular function is essential especially in patients with cardiopulmonary disease and respiratory muscle weakness.
    • During treatment with Baclofen, neurogenic disturbances affecting emptying of the bladder may improve. However in patients with preexisting sphincter hypertonia, acute retention of urine may occur. Baclofen should be used with caution in these circumstances.
    • Baclofen has not significantly benefited patients with stroke. These patients have also shown poor tolerance to the medicine.
    • Appropriate laboratory tests should be performed periodically in patients with hepatic diseases or diabetes mellitus to ensure that no medicine induced changes in these underlying diseases have occurred.
    InteractionsView
    • Increased sedation may occur if Baclofen is taken with agents acting on the central nervous system, alcohol or synthetic opiates. The risk of respiratory depression is also increased.
    • Combined treatment with Baclofen and antihypertensives is likely to increase the fall in blood pressure; therefore the dosage of antihypertensive medication should be adjusted accordingly.
    • The concomitant administration of Baclofen and tricyclic antidepressants may potentiate the pharmacological effects of Baclofen resulting in pronounced muscular hypotonia.
    • In patients with Parkinsons disease receiving treatment with Baclofen and levodopa and carbidopa, there have been several reports of mental confusion, hallucinations, headaches, nausea and agitation.
    • The concurrent use of MAO inhibitors and Baclofen may result in increased CNS depressant effects. Caution is advised and the dosage of one or both agents should be adjusted accordingly.
    • Caution should be exercised when administering Baclofen and magnesium sulphate or other neuromuscular blocking agents since a synergistic effect may theoretically occur.
    Pregnancy & lactationView
    Pregnancy category B3. Safe use of Baclofen during pregnancy has not been established. Baclofen crosses the placental barrier. Baclofen should only be administered to pregnant women when in the judgement of the physician concludes that the potential benefits outweigh the possible hazards. Baclofen is excreted in breast milk however evidence to date suggests that the quantities are so small that no undesirable effects on the infant would be expected.
    Overdose effectsView
    Gastric lavage is important in case of severe overdose.
    StorageView
    Keep below 30°C temperature, away from light & moisture. Keep out of the reach of children.

    Relor

    Loratadine
    Tablet 10 mg Allopathic Non-sedating antihistamines

    Indications

    Urticaria

    Indication detailsView
    Loratadine tablet provides fast, effective relief from the symptoms of seasonal allergic rhinitis, perennial allergic rhinitis and skin allergies including chronic urticaria. It is also effective in alleviating symptoms of allergic rhinitis such as sneezing, nasal discharge, itching, ocular itching and burning. Nasal and ocular sign and symptoms are relieved rapidly after oral administration. Loratadine tablet is also indicated in idiopathic urticaria. In children over 2 years Loratadine tablet is indicated for the symptomatic relief of seasonal allergic rhinitis and allergic skin conditions such as urticaria, nettlerash.
    Therapeutic classView
    Non-sedating antihistamines
    PharmacologyView
    This tablet is a preparation of Loratadine. Loratadine is a non-sedative histamine Hr receptor antagonist with antiallergic properties. Loratadine is a long-acting tricyclic antihistamine with selective peripheral Hi-receptor antagonistic activity and no central sedative or anticholinergic effect. It is rapidly effective and long-lasting, allowing once-a-day administration.
    DosageView
    Adults and children over 12 years of age: One Loratadine tablet once daily. It is usually administered in the morning or when symptoms require treatment.

    Children 2-12 years: Body weight over 30 kg: one Loratadine tablet once daily, below 30 kg: half Loratadine tablet once daily.

    Below 2 years of age: Loratadine tablet is not recommended for use below 2 years of age since safety and efficacy has not been established.
    Side effectsView
    During controlled clinical studies the incidence of adverse events, including sedation and anticholinergic effects observed with 10 mg Loratadine was comparable to that observed with placebo. Studies on the effect of Loratadine on actual driving performance, and on tests of cognitive and psychomotor functioning have shown it to be comparable to placebo.
    ContraindicationsView
    Loratadine is contraindicated in patients who have shown hypersensitivity or idiosyncrasy to their components.
    PrecautionsView
    Caution should be taken in patients with liver impairment or renal insufficiency (eGFR <30 ml/min).
    InteractionsView
    There are no reports of potentially hazardous interactions with other drugs. In contrast to many other histamine H1 receptor antagonists, Loratadine has no potentiating effects when administered concurrently with alcohol, as measured by psychomotor performance studies. Concomitant therapy with drugs that inhibit or are metabolized by hepatic cytochromes P450 3A4 and 2D6 may elevate plasma concentrations of either drug and this mayifesult in adverse effects. Cimetidine inhibits both enzymes while erythromycin or ketoconazole inhibits P450 3A4. These drugs increase loratadine serum concentrations but no adverse effects are reported.
    Pregnancy & lactationView
    There is no experience of the use of Loratadine in human pregnancy. Therefore its use during pregnancy is not advisable. Loratadine is excreted in breast milk in a very small amount. So nursing mothers are advised not to take the drug.
    Overdose effectsView
    In adults somnolence, tachycardia and headache have been reported with overdose greater than 10 mg. Extrapyramidal signs and palpitations have been reported in children with overdoses of greater than 10 mg. In the event of overdosage, general symptomatic and supportive measures should be instituted promptly and maintained for as long as necessary. It would seem reasonable to treat patients presenting early after large overdoses with oral activated charcoal. The conscious patients may be induced to vomit or gastric lavage may be performed.
    StorageView
    Keep in a dry place away from light and heat. Keep out of the reach of children.

    Relsin

    Silodosin
    Capsule 8 mg Allopathic BPH/ Urinary retention/ Urinary incontinence

    Indications

    Benign prostatic hyperplasia (BPH)

    Indication detailsView
    Silodosin, a selective alpha-1 adrenergic receptor antagonist, is indicated for the treatment of the signs and symptoms of benign prostatic hyperplasia (BPH). Silodosin is not indicated for the treatment of hypertension.
    • Highly effective for the treatment of Benign Prostatic Hyperplasia.
    • Highest uroselectivity to alpha-1 adrenergic receptor.
    • Effective treatment option for BPH who are not responding to Tamsulosin.
    • Dose not cause Orthostatic hypotension.
    • Convenient once-daily dosing.
    Therapeutic classView
    BPH/ Urinary retention/ Urinary incontinence
    PharmacologyView
    Silodosin is a selective antagonist of post-synaptic alpha-1 adrenoreceptors, which are located in the human prostate, bladder base, bladder neck, prostatic capsule and prostatic urethra. Blockade of these alpha-1 adrenoreceptors can cause smooth muscle in these tissues to relax, resulting in an improvement in urine flow and a reduction in BPH symptoms.
    DosageView
    The recommended dose is Silodosin 8 mg orally once daily with a meal. 4 mg capsules taken orally once daily with a meal for those with moderate renal impairment (CrCl 30-50 mL/min).
    Side effectsView
    Most common adverse reactions are retrograde ejaculation, dizziness, diarrhea, orthostatic hypotension, headache, nasopharyngitis and nasal congestion.
    ContraindicationsView
    Patients with severe renal & hepatic impairment, concomitant administration with strong Cytochrome P450 3A4 (CYP3A4) inhibitors (e.g., ketoconazole, clarithromycin, itraconazole, ritonavir) and patients with a history of hypersensitivity to Silodosin.
    PrecautionsView
    Postural hypotension with or without symptoms (e.g. dizziness) may develop when beginning Silodosin treatment. Silodosin should not be used in combination with other alpha-blocker. Inform patients planning cataract surgery to notify their ophthalmologist that they are taking Silodosin because of the possibility of Intraoperative Floppy Iris Syndrome (IFIS)
    InteractionsView
    Strong P-glycoprotein inhibitors (e.g., cyclosporine): Co-administration may increase plasma Silodosin concentration. Concomitant use of PDE5 inhibitors with alpha-blockers including Silodosin can potentially cause symptomatic hypotension.
    Pregnancy & lactationView
    Pregnancy Category B. Silodosin is not indicated for use in women. An embryo/fetal study in rabbits showed decreased maternal body weight at 200 mg/kg/day (approximately 13-25 times the maximum recommended human exposure or MRHE of Silodosin via AUC). No statistically significant teratogenicity was observed at this dose. Silodosin was not teratogenic when administered to pregnant rats during organogenesis at 1000 mg/kg/day (estimated to be approximately 20 times the MRHE). No maternal or fetal effects were observed at this dose. Rats and rabbits do not produce glucuronidated Silodosin, which is present in human serum at approximately 4 times the level of circulating Silodosin and which has similar pharmacological activity to Silodosin. No effects on physical or behavioral development of offspring were observed when rats were treated during pregnancy and lactation at up to 300 mg/kg/day.
    Pediatric usageView
    Pediatric patients: Silodosin is not indicated for use in pediatric patients.

    Geriatric use: In double-blind, placebo-controlled, 12-week clinical studies of Silodosin, 259 (55.6%) were under 65 years of age, 207 (44.4%) patients were 65 years of age and over, while 60 (12.9%) patients were 75 years of age and over. Orthostatic hypotension was reported in 2.3% of Silodosin patients < 65 years of age (1.2% for placebo), 2.9% of Silodosin patients > 65 years of age (1.9% for placebo), and 5.0% of patients > 75 years of age (0% for placebo). There were otherwise no significant differences in safety or effectiveness between older and younger patients.

    Renal impairment: Silodosin is contra-indicated in patients with severe renal impairment (CCr <30 mL/min). In patients with moderate renal impairment (CCr 30-50 mL/min), the dose should be reduced to Silodosin 4 mg once daily taken with a meal. No dosage adjustment is needed in patients with mild renal impairment (CCr 50-80 mL/min).

    Hepatic impairment: Silodosin has not been studied in patients with severe hepatic impairment (Child-Pugh score >10) and is therefore contra-indicated in these patients. No dosage adjustment is needed in patients with mild or moderate hepatic impairment.
    Overdose effectsView
    Silodosin was evaluated at doses of up to 48 mg/day in healthy male subjects. The dose-limiting adverse event was postural hypotension. Should overdose of Silodosin lead to hypotension, support of the cardiovascular system is of first importance. Restoration of blood pressure and normalization of heart rate may be accomplished by maintaining the patient in the supine position. If this measure is inadequate, administration of intravenous fluid should be considered. If necessary, vasopressors could be used, and renal function should be monitored and supported as needed. Dialysis is unlikely to be of significant benefit since Silodosin is highly (97%) protein bound.
    StorageView
    Store at below 30°C in a dry place protected from light. Keep out of reach of Children.

    Relsin

    Silodosin
    Capsule 4 mg Allopathic BPH/ Urinary retention/ Urinary incontinence

    Indications

    Benign prostatic hyperplasia (BPH)

    Indication detailsView
    Silodosin, a selective alpha-1 adrenergic receptor antagonist, is indicated for the treatment of the signs and symptoms of benign prostatic hyperplasia (BPH). Silodosin is not indicated for the treatment of hypertension.
    • Highly effective for the treatment of Benign Prostatic Hyperplasia.
    • Highest uroselectivity to alpha-1 adrenergic receptor.
    • Effective treatment option for BPH who are not responding to Tamsulosin.
    • Dose not cause Orthostatic hypotension.
    • Convenient once-daily dosing.
    Therapeutic classView
    BPH/ Urinary retention/ Urinary incontinence
    PharmacologyView
    Silodosin is a selective antagonist of post-synaptic alpha-1 adrenoreceptors, which are located in the human prostate, bladder base, bladder neck, prostatic capsule and prostatic urethra. Blockade of these alpha-1 adrenoreceptors can cause smooth muscle in these tissues to relax, resulting in an improvement in urine flow and a reduction in BPH symptoms.
    DosageView
    The recommended dose is Silodosin 8 mg orally once daily with a meal. 4 mg capsules taken orally once daily with a meal for those with moderate renal impairment (CrCl 30-50 mL/min).
    Side effectsView
    Most common adverse reactions are retrograde ejaculation, dizziness, diarrhea, orthostatic hypotension, headache, nasopharyngitis and nasal congestion.
    ContraindicationsView
    Patients with severe renal & hepatic impairment, concomitant administration with strong Cytochrome P450 3A4 (CYP3A4) inhibitors (e.g., ketoconazole, clarithromycin, itraconazole, ritonavir) and patients with a history of hypersensitivity to Silodosin.
    PrecautionsView
    Postural hypotension with or without symptoms (e.g. dizziness) may develop when beginning Silodosin treatment. Silodosin should not be used in combination with other alpha-blocker. Inform patients planning cataract surgery to notify their ophthalmologist that they are taking Silodosin because of the possibility of Intraoperative Floppy Iris Syndrome (IFIS)
    InteractionsView
    Strong P-glycoprotein inhibitors (e.g., cyclosporine): Co-administration may increase plasma Silodosin concentration. Concomitant use of PDE5 inhibitors with alpha-blockers including Silodosin can potentially cause symptomatic hypotension.
    Pregnancy & lactationView
    Pregnancy Category B. Silodosin is not indicated for use in women. An embryo/fetal study in rabbits showed decreased maternal body weight at 200 mg/kg/day (approximately 13-25 times the maximum recommended human exposure or MRHE of Silodosin via AUC). No statistically significant teratogenicity was observed at this dose. Silodosin was not teratogenic when administered to pregnant rats during organogenesis at 1000 mg/kg/day (estimated to be approximately 20 times the MRHE). No maternal or fetal effects were observed at this dose. Rats and rabbits do not produce glucuronidated Silodosin, which is present in human serum at approximately 4 times the level of circulating Silodosin and which has similar pharmacological activity to Silodosin. No effects on physical or behavioral development of offspring were observed when rats were treated during pregnancy and lactation at up to 300 mg/kg/day.
    Pediatric usageView
    Pediatric patients: Silodosin is not indicated for use in pediatric patients.

    Geriatric use: In double-blind, placebo-controlled, 12-week clinical studies of Silodosin, 259 (55.6%) were under 65 years of age, 207 (44.4%) patients were 65 years of age and over, while 60 (12.9%) patients were 75 years of age and over. Orthostatic hypotension was reported in 2.3% of Silodosin patients < 65 years of age (1.2% for placebo), 2.9% of Silodosin patients > 65 years of age (1.9% for placebo), and 5.0% of patients > 75 years of age (0% for placebo). There were otherwise no significant differences in safety or effectiveness between older and younger patients.

    Renal impairment: Silodosin is contra-indicated in patients with severe renal impairment (CCr <30 mL/min). In patients with moderate renal impairment (CCr 30-50 mL/min), the dose should be reduced to Silodosin 4 mg once daily taken with a meal. No dosage adjustment is needed in patients with mild renal impairment (CCr 50-80 mL/min).

    Hepatic impairment: Silodosin has not been studied in patients with severe hepatic impairment (Child-Pugh score >10) and is therefore contra-indicated in these patients. No dosage adjustment is needed in patients with mild or moderate hepatic impairment.
    Overdose effectsView
    Silodosin was evaluated at doses of up to 48 mg/day in healthy male subjects. The dose-limiting adverse event was postural hypotension. Should overdose of Silodosin lead to hypotension, support of the cardiovascular system is of first importance. Restoration of blood pressure and normalization of heart rate may be accomplished by maintaining the patient in the supine position. If this measure is inadequate, administration of intravenous fluid should be considered. If necessary, vasopressors could be used, and renal function should be monitored and supported as needed. Dialysis is unlikely to be of significant benefit since Silodosin is highly (97%) protein bound.
    StorageView
    Store at below 30°C in a dry place protected from light. Keep out of reach of Children.

    Relupros

    Relugolix
    Tablet 120 mg Allopathic Gonadotropin-releasing hormone (GnRH) antagonist
    Indication detailsView
    Relugolix tablet is a gonadotropin-releasing hormone (GnRH) receptor antagonist indicated for the treatment of adult patients with advanced prostate cancer.
    Therapeutic classView
    Gonadotropin-releasing hormone (GnRH) antagonist
    PharmacologyView
    Relugolix is a non-peptide small molecule, GnRH receptor antagonist. Relugolix competitively binds to pituitary GnRH receptors, thereby, reducing the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), and consequently testosterone.

    Absorption: Relugolix is a substrate for intestinal P-gp. The mean (CV%) absolute bioavailability of Relugolix is approximately 12%. The median (range) Tmax of Relugolix is 2.25 hours.

    Effect of Food: No clinically meaningful differences in the pharmacokinetics of Relugolix were observed following consumption of a high-calorie, high-fat meal.

    Distribution: Plasma protein binding of Relugolix is 68 to 71%, primarily to albumin and to a lesser extent to α1- acid glycoprotein. The mean blood-to-plasma ratio is 0.78.

    Elimination: The mean effective half-life of Relugolix is 25 hours and the mean (CV %) terminal elimination half-life is 60.8 (11%) hours. The mean (CV %) total clearance of Relugolix is 29.4 (15%) L/h and the renal clearance is 8 L/h.

    Metabolism: Relugolix is metabolized primarily by CYP3A and to a lesser extent by CYP2C8 in vitro.

    Excretion: After oral administration of a single 80mg radiolabeled dose of Relugolix, approximately 81% of the radioactivity was recovered in feces (4.2% as unchanged) and 4.1% in urine (2.2% as unchanged).
    DosageView
    A loading dose of 360 mg on the first day of treatment followed by 120 mg taken once daily, at approximately the same time each day. Relugolix Tablet can be taken with or without food. Advise patients to take a missed dose of Relugolix as soon as they remember. If the dose was missed by more than 12 hours, patients should not take the missed dose and resume with the next scheduled dose. If treatment with Relugolix is interrupted for greater than 7 days, restart Relugolix with a loading dose of 360 mg on the first day, and continue with a dose of 120 mg once daily.

    Pediatric Use: The safety and efficacy of Relugolix in pediatric patients have not been established.

    Geriatric Use: No overall differences in safety or effectiveness were observed between older and younger subjects.
    Side effectsView
    Adverse Reactions: The most common adverse reactions (≥10%) and laboratory abnormalities (≥15%) were hot flushes, glucose increased, triglycerides increased, musculoskeletal pain, haemoglobin decreased, alanine aminotransferase (ALT) increased, fatigue, aspartate aminotransferase (AST) increased, constipation, and diarrhea.

    Common Side Effects    : Hot flushes, Increased blood sugar levels, Increased blood fat (triglyceride) levels, Muscle and joint pain, Decreased hemoglobin levels, Increased liver enzymes, Tiredness, Constipation, Diarrhoea

    Rare Side Effects: Relugolix may cause rare side effects, including Changes in the electrical activity of your heart (QT prolongation), Dizziness, Fainting, Feeling that your heart is pounding or racing (palpitations), Chest pain. Other side effects include weight gain, decreased sex drive, and erectile function problems.
    PrecautionsView
    QT/QTc Interval Prolongation: Androgen deprivation therapy may prolong the QT interval.

    Embryo-Fetal Toxicity: Relugolix can cause fetal harm. Advise males with female partners of reproductive potential to use effective contraception.
    InteractionsView
    P-gp Inhibitors: Avoid co-administration. If unavoidable, take Relugolix first, separate dosing by at least 6 hours, and monitor patients more frequently for adverse reactions. Combined P-gp and

    Strong CYP3A Inducers: Avoid co-administration. If unavoidable, increase the Relupros ® dose to 240 mg once daily.
    Pregnancy & lactationView
    The safety and efficacy of Relugolix at the recommended dose of 120 mg daily have not been established in females. Females and Males of Reproductive Potential. Based on findings in animals and mechanism of action, Relugolix may impair fertility in males of reproductive potential.
    Overdose effectsView
    There is no specific experience in the management of Relugolix overdose in patients.
    StorageView
    Store in a cool and dry place, protect from light & moisture. Keep all medicines out of the reach of children.

    Relux

    Flupentixol + Melitracen
    Tablet 0.5 mg+10 mg Allopathic Combined anxiolytics & anti-depressant drugs

    Indications

    Psychosis

    Indication detailsView
    Flupentixol and Melitracen tablet is indicated in-
    • Anxiety
    • Depression
    • Apathy
    • Psychogenic depression.
    • Depressive neurosses.
    • Masked depression.
    • Psychosomatic affections accompanied by anxiety and apathy.
    • Menopausal depressions.
    • Dysphoria and depression in alcoholics and drug addicts.
    Therapeutic classView
    Combined anxiolytics & anti-depressant drugs
    PharmacologyView
    This consists of two well known and well proven compounds: flupentixol-a neuroleptic with anxiolytic and antidepressant properties of its own when given in small doses, and melitracen-a bipolar thymoleptic with activating properties in low doses. In combination the compounds render a preparation with antidepressant, anxiolytic and activating properties. Maximal serum concentration is reached in about 4 hours after oral administration of flupentixol and in about 4 hours after oral administration of melitracen. The biological half-life of flupentixol is about 35 hours and that of melitracen is about 19 hours. The combination of flupentixol and melitracen does not seem to influence the pharmacokinetic properties of the individual compounds.
    DosageView
    Adults: Usually 2 tablets orally daily in the morning and noon. In severe cases, the morning dose may be increased to 2 tablets.

    Elderly patients: 1 tablet in the morning.

    Maintenance dose: Usually 1 tablet orally in the morning. In cases of insomnia or severe restlessness, additional treatment with a sedative in the acute phase is recommended.
    Side effectsView
    In the recommended doses side effects are rare. These could be transient restlessness and insomnia.
    ContraindicationsView
    • The immediate recovery phase after myocardial infarction.
    • Defects in bundle-branch conduction.
    • Untreated narrow-angle glaucoma.
    • Acute alcohol, barbiturate and opiate intoxications.
    • This tablet should not be given to patients who have received an MAO-inhibitor within two weeks.
    • Not recommended for excitable or overactive patients since its activating effect may lead to exaggeration of these characteristics.
    PrecautionsView
    If previously the patient has been treated with tranquillizers with sedative effect these should be withdrawn gradually.
    InteractionsView
    This tablet may enhance the response to alcohol, barbiturates and other CNS depressants. Simultaneous administration of MAO-inhibitors may cause hypertensive crises. Neuroleptics and thymoleptics reduce the antihypertensive effect of guanethidine and similar acting compounds and thymoleptics enhance the effects of adrenaline and noradrenaline.
    Pregnancy & lactationView
    This tablet should preferably not be given during pregnancy and lactation.
    Overdose effectsView
    In cases of overdosage the symptoms of intoxications by melitracen, especially of anticholinergic nature, dominate. More rarely extrapyramidal symptoms due to flupentixol occur. Symptomatic and Supportive. Gastric lavage should be carried out as soon as possible and activated charcoal may be administered. Measures aimed at supporting the respiratory and cardiovascular systems should be instituted. Epinephrine (adrenaline) must not be used for such patients. Convulsions may be treated with diazepam and extrapyramidal symptoms with biperiden.
    StorageView
    Store at a temperature not exceeding 30°C in a dry place. Protect from light. Keep out of reach of children.

    Relvis

    Tiemonium Methylsulphate
    IM/IV Injection 5 mg/2 ml Allopathic Anticholinergics

    Indications

    Visceral muscle spasm

    Indication detailsView
    Tiemonium Methylsulphate is an antispasmodic drug that reduces muscles spasm of the intestine, biliary system, bladder and uterus. It is used in symptomatic treatment of pain related to functional disorders of the digestive tract and biliary system. It is also indicated for the treatment of spasm and pain in urological and gynaecological diseases.
    Therapeutic classView
    Anticholinergics
    PharmacologyView
    Tiemonium Methylsulphate a competitive antagonist of Acetylcholine, Histamine and strengthens of calcium bond with membrane phospholipids and proteins. Thus inhibits intracellular contractile protein of visceral cell which causes inhibition of visceral spasm and pain.
    DosageView
    Tablet/Syrup-
    • Adult: usual dose is 2-6 tablets or 3-9 teaspoonfuls syrup daily in divided doses.
    • Children: 3 ml/kg or 6 mg/kg body weight daily in divided doses.
    Injection: 1 Tiemonium Methylsulphate Injection 3 times daily, through Intravenous route slowly or Intramuscular route.

    Suppository: 20 mg Tiemonium Methylsulphate suppository two or three times daily, through rectal route.
    Side effectsView
    Tiemonium Methylsulphate may have the risk of hypotension & tachycardia in certain individuals.
    ContraindicationsView
    It should not be used in urethroprostatic disorder involving a risk of urine retension. It is contraindicated in patient with having risk of angle closure glaucoma.
    PrecautionsView
    Caution should be taken during treatment of patients with disorders of the prostate. Caution should also be taken in case of chronic bronchitis, coronary insufficiency, ambient hyperthermia, renal & hepatic insufficiency. The risks of visual disturbances can make it dangerous to drive or use machines.
    InteractionsView
    Tiemonium methylsulphate tablet should not be used with other drugs without prior consult of a registered physician to avoid possible drug interaction.
    Pregnancy & lactationView
    The results of animal studies of Tiemonium Methylsulphate did not reveal any teratogenic effects; no deformities have been reported up till now with normal use. In absence of sufficient data, prudence should be the rule for nursing mothers although no problems have been reported with normal use.
    Pediatric usageView
    Paediatric use: safety and effectiveness of Tiemonium methylsulphate in paediatric patients have not been established.

    Geriatric use: Efficacy and safety were maintained with increasing age.
    Overdose effectsView
    There is not available data regarding the overdose of Tiemonium methylsulphate tablet.
    StorageView
    Keep in a dry place, away from light and heat. Keep out of the reach of children.

    Relvis

    Tiemonium Methylsulphate
    Tablet 50 mg Allopathic Anticholinergics

    Indications

    Visceral muscle spasm

    Indication detailsView
    Tiemonium Methylsulphate is an antispasmodic drug that reduces muscles spasm of the intestine, biliary system, bladder and uterus. It is used in symptomatic treatment of pain related to functional disorders of the digestive tract and biliary system. It is also indicated for the treatment of spasm and pain in urological and gynaecological diseases.
    Therapeutic classView
    Anticholinergics
    PharmacologyView
    Tiemonium Methylsulphate a competitive antagonist of Acetylcholine, Histamine and strengthens of calcium bond with membrane phospholipids and proteins. Thus inhibits intracellular contractile protein of visceral cell which causes inhibition of visceral spasm and pain.
    DosageView
    Tablet/Syrup-
    • Adult: usual dose is 2-6 tablets or 3-9 teaspoonfuls syrup daily in divided doses.
    • Children: 3 ml/kg or 6 mg/kg body weight daily in divided doses.
    Injection: 1 Tiemonium Methylsulphate Injection 3 times daily, through Intravenous route slowly or Intramuscular route.

    Suppository: 20 mg Tiemonium Methylsulphate suppository two or three times daily, through rectal route.
    Side effectsView
    Tiemonium Methylsulphate may have the risk of hypotension & tachycardia in certain individuals.
    ContraindicationsView
    It should not be used in urethroprostatic disorder involving a risk of urine retension. It is contraindicated in patient with having risk of angle closure glaucoma.
    PrecautionsView
    Caution should be taken during treatment of patients with disorders of the prostate. Caution should also be taken in case of chronic bronchitis, coronary insufficiency, ambient hyperthermia, renal & hepatic insufficiency. The risks of visual disturbances can make it dangerous to drive or use machines.
    InteractionsView
    Tiemonium methylsulphate tablet should not be used with other drugs without prior consult of a registered physician to avoid possible drug interaction.
    Pregnancy & lactationView
    The results of animal studies of Tiemonium Methylsulphate did not reveal any teratogenic effects; no deformities have been reported up till now with normal use. In absence of sufficient data, prudence should be the rule for nursing mothers although no problems have been reported with normal use.
    Pediatric usageView
    Paediatric use: safety and effectiveness of Tiemonium methylsulphate in paediatric patients have not been established.

    Geriatric use: Efficacy and safety were maintained with increasing age.
    Overdose effectsView
    There is not available data regarding the overdose of Tiemonium methylsulphate tablet.
    StorageView
    Keep in a dry place, away from light and heat. Keep out of the reach of children.

    Relye

    Bromfenac Sodium
    Ophthalmic Solution 0.09% Allopathic Ophthalmic Non-Steroid drugs

    Indications

    Postoperative ocular inflammation

    Indication detailsView
    Bromfenac is indicated for the treatment of postoperative inflammation and the reduction of ocular pain in patients who have undergone cataract extraction
    Therapeutic classView
    Ophthalmic Non-Steroid drugs
    PharmacologyView
    Bromfenac is a nonsteroidal anti-inflammatory drug (NSAID). The mechanism of anti-inflammatory activity is thought to be due to its ability to block prostaglandin synthesis by inhibiting cyclooxygenase 1 and 2. Prostaglandins have been shown in many animal models to be mediators of certain kinds of intraocular inflammation. In studies performed in animal eyes, prostaglandins have been shown to produce disruption of the blood-aqueous humor barrier, vasodilation, increased vascular permeability, leukocytosis and increased intraocular pressure.
    DosageView
    Adults: 1 drop to the problem eye 2 times a day; treatment should start 24 hours after surgery and should continue for 2 weeks

    Children: Use and dose must be determined by the doctor.

    Pediatric Use: Safety and efficacy in pediatric patients below the age of 18 have not been established yet.
    Side effectsView
    The most commonly reported adverse reactions following use of Bromfenac after cataract surgery include: abnormal sensation in eye, conjunctival hyperemia, eye irritation (including burning/stinging), eye pain, eye pruritus, eye redness, headache and iritis. These events were reported in 2-7% of patients
    ContraindicationsView
    Bromfenac ophthalmic solution is contraindicated in patients with known hypersensitivity to any ingredients of the formulation.
    PrecautionsView
    All topical NSAIDs may slow or delay healing. Topical corticosteroids are also known to slow or delay healing. Concomitant use of topical NSAIDs and topical steroids may increase the potential for healing problems. It is recommended that Bromfenac ophthalmic solution be used with caution in patients with known bleeding tendencies or who are receiving other medications which may prolong bleeding time. Bromfenac ophthalmic solution should not be administered while wearing contact lenses.

    Bromfenac ophthalmic solution contains Sodium Sulfite, a compound that may cause allergic-type reactions including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain susceptible people. The overall prevalence of sulfite sensitivity in the general population is unknown and probably low. Therefore, caution should be used when treating individuals who have previously exhibited sensitivities to these drugs.
    Pregnancy & lactationView
    Pregnancy Category C. This drug should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Caution should be exercised when Bromfenac ophthalmic solution is administered to a nursing mother.
    StorageView
    Keep out of the reach of children. Store in a cool, dry place, away from heat and direct light.  Do not use more than 4 weeks after opening.

    Relyto

    Rituximab
    IV Infusion 10 mg/ml Allopathic Cytotoxic immunosuppressants

    Indications

    Rheumatoid arthritis

    Indication detailsView
    Non-Hodgkin's Lymphoma (NHL): Rituximab is indicated for the treatment of patients with-
    • Relapsed or refractory, low-grade or follicular, CD20-positive, B-cell NHL as a single agent
    • Previously untreated follicular, CD20-positive, B-cell NHL in combination with first line chemotherapy and, in patients achieving a complete or partial response to Rituxan in combination with chemotherapy, as single-agent maintenance therapy.
    • Non-progressing (including stable disease), low-grade, CD20-positive, B-cell NHL as a single agent after first-line CVP chemotherapy
    • Previously untreated diffuse large B-cell, CD20-positive NHL in combination with CHOP or other anthracycline-based chemotherapy regimens
    Chronic Lymphocytic Leukemia (CLL): Rituximab is indicated, in combination with fludarabine and cyclophosphamide (FC), for the treatment of patients with previously untreated and previously treated CD20-positive CLL.

    Rheumatoid Arthritis (RA): Rituximab in combination with methotrexate is indicated for the treatment of adult patients with moderately- to severely- active rheumatoid arthritis who have had an inadequate response to one or more TNF antagonist therapies.

    Granulomatos Is With Polyangiitis (GPA) (Wegener's Granulomatosis) and Microscopic Polyangiitis (MPA): Rituximab, in combination with glucocorticoids, is indicated for the treatment of adult patients with Granulomatosis with Polyangiitis (GPA) (Wegener's Granulomatosis) andMicroscopic Polyangiitis (MPA).
    Therapeutic classView
    Cytotoxic immunosuppressants
    PharmacologyView
    Rituximab is a chimeric monoclonal antibody to CD20 antigen which regulates cell cycle initiation. It binds to the antigen on the cell surface, activating complement-dependent B-cell cytotoxicity; and to human Fc receptors, mediating cell killing through an antibody-dependent cellular toxicity.

    Duration: Detectable in serum 3-6 mth after completion of therapy; B-cell recovery 6-12 mth following completion of therapy.
    DosageView
    Intravenous (Adult)-

    Non-Hodgkin's lymphoma, Refractory or relapsed follicular lymphoma: As a single agent, 375 mg/m2 infusion once wkly, for 4 doses at an initial rate of 50 mg/hr. May increase by 50 mg/hr every 30 min. If tolerated, subsequent infusions can be started at 100 mg/hr and increased by 100 mg/hr every 30 min. Max rate: 400 mg/hr. When used with CVP (cyclophosphamide, vincristine and prednisolone) for follicular lymphoma or CHOP (cyclophosphamide, doxorubicin, vincristine and prednisone) for diffuse large B-cell lymphoma, 375 mg/m2 given on day 1 of the chemotherapy cycle after corticosteroid regimen, for up to 8 cycles. For patients who were treated with 6-8 cycles of CVP chemotherapy and have not progressed, 375 mg/m2 may be given once wkly for 4 doses, may repeat every 6 mth, for up to 16 doses. Maintenance: 375 mg/m2 given once every 3 mth (those who have responded to induction chemotherapy), once every 2 mth initiated 2 mth after the last dose of induction chemotherapy (previously untreated) for a max period of 2 yr.

    Chronic lymphocytic leukaemia: 375 mg/m2, given on the day prior to chemotherapy in cycle 1, followed by 500 mg/m2 on day 1 (every 28 days) of cycles 2-6.

    Rheumatoid arthritis: Given as two 1 g IV infusion doses, separated by 2 wk and in combination with methotrexate. Corticosteroids may be given before each infusion to minimise the risk and severity of infusion reactions.
    Side effectsView
    Reactivation of hepatitis B virus. Fever and rigors. Pruritus, skin rashes, dyspnoea, bronchospasm, angioedema, transient hypotension, and flushing, asthenia, headache, rhinitis, thrombocytopenia, neutropenia, anaemia, abdominal pain, bowel obstruction, and perforation. Exacerbation of heart failure and angina pectoris. Reversible interstitial pneumonia and interstitial fibrosis. Depletion of immunoglobulin concentrations.
    ContraindicationsView
    Hypersensitivity to murine proteins. Patients with active, severe infections. Severely immunocompromised state. Concomitant use with live viral vaccines. Lactation.
    PrecautionsView
    Extensive tumour burden, pulmonary insufficiency or pulmonary tumour infiltration; history of cardiac disease. Pregnancy.
    InteractionsView
    Increased risk of renal toxicity with cisplatin.
    Pregnancy & lactationView
    Pregnancy Category C. Either studies in animals have revealed adverse effects on the foetus (teratogenic or embryocidal or other) and there are no controlled studies in women or studies in women and animals are not available. Drugs should be given only if the potential benefit justifies the potential risk to the foetus.
    ReconstitutionView
    Dilute the appropriate dose with sodium chloride 0.9% or glucose 5% to a final concentration of between 1 and 4 mg/mL.
    StorageView
    Store between 2-8° C.

    Rem

    Bromazepam
    Tablet 3 mg Allopathic Benzodiazepine sedatives

    Indications

    Panic attack

    Indication detailsView
    Bromazepam is indicated in-
    • Emotional disturbances, i.e. acute tension and anxiety states. Difficulties in interpersonal contact. Agitation, insomnia, anxious and agitated depressive reactions.
    • Functional disturbances in the cardiovascular and respiratory systems, i.e. pseudoangina pectoris, pericardial anxiety, tachycardia, emotiogenic hypertension, dyspnea and hyperventilation.
    • Disturbances in the gastrointestinal tract, i.e. irritable bowel syndrome, epigastric pain, spasm, bloating diarrhea etc.
    • Disturbances in the urinary tract, i.e. frequency, irritable bladder and dysmenorrhea.
    • Psychosomatic disorder, i.e. psychogenic headache, asthma, gastric and duodenal ulcer.
    • It is also indicated in emotional reactions to chronic organic disease.
    Therapeutic classView
    Benzodiazepine sedatives
    PharmacologyView
    Bromazepam is a powerful psychotropic agent. In lower dosage, it selectively reduces tension and anxiety. In higher dosage, it shows sedative and muscle-relaxant properties. Bromazepam binds to the GABA-A receptor producing a conformational change and potentiating its inhibitory effects. Other neurotransmitters are not influenced.
    DosageView
    Standard dosage: Average dosage for outpatient therapy is 1.5-3 mg up to three times daily. Treatment of outpatients should begin with low doses, gradually increasing to the optimum level.

    In severe cases, especially in hospital: 6-12 mg 2 or 3 times daily. The overall treatment generally should not be more than 8-12 weeks. In certain cases extension beyond the maximum treatment period may be necessary; if so, it should be taken with re-evaluation of the patient's status with special expertise.

    Elderly and debilitated patients: Elderly patients and those with impaired hepatic functions require lower doses.

    Children: Bromazepam is usually not indicated in children, but if the physician feels bromazepam treatment is appropriate, then the dose should be adjusted to their low bodyweight (about 0.1-0.3 mg/kg bodyweight)
    AdministrationView
    Bromazepam tablets are for oral administration
    Side effectsView
    Common side-effects include fatigue, drowsiness, muscle weakness, numbed muscle, reduced alertness, confusion, headache, ataxia etc. These phenomena occur predominantly at the start of therapy and usually disappear with prolonged administration. Anterograde amnesia may occur using therapeutic doses.
    ContraindicationsView
    Bromazepam is contraindicated in patients with known hypersensitivity to bromazepam, severe respiratory insufficiency, severe hepatic insufficiency or sleep apnea syndrome.
    PrecautionsView
    The use of benzodiazepines and benzodiazepine like agents may lead to the development of physical and psychological dependence upon these products. This dependence depends on the dose and duration of treatment; it is also greater in predisposed patients with a history of alcohol. Once physical dependence has developed, termination of the treatment will be accompanied by withdrawal symptoms. These may consist of headache, muscle pain, extreme anxiety, tension, confusion and irritability. Since the risk of withdrawal phenomena and rebound phenomena is greater after abrupt discontinuation of the treatment, it is recommended that the dosage be decreased gradually. Bromazepam is not recommended for the primary treatment of sleeplessness caused by psychotic illness. Caution should be exercised while driving cars or using machineries.
    InteractionsView
    If bromazepam is combined with other centrally active drugs, its sedative effects may be enhanced. These drugs are antidepressants, hypnotics, narcotics, antipsychotics, sedatives, antiepileptic drugs, sedative antihistamines and anesthetics. Co-administration of cimetidine may prolong the eliminiation half-life of bromazepam. Concomitant intake of bromazepam with alcohol should be avoided, because the sedative effect of bromazepam may be intensified by alcohol.
    Pregnancy & lactationView
    The safety of bromazepam during pregnancy has not been established. As bromazepam is excreted in breast milk, use should be avoided during lactation.
    StorageView
    Keep in a dry place away from light and heat. Keep out of the reach of children.